NEULANDLAB.BO
NEULANDLAB.BO
INE794A01010
NEULAND LABORATORIES LTD.
Loading chart...

Company Profile

Neuland Laboratories Limited engages in the manufacture and sale of active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. It also provides custom manufacturing solutions, generic drug substances, as well as peptide APIs and synthesis services. The company serves generic companies, regional and domestic pharmaceutical manufacturers, distributors, and other pharmaceutical and biotechnology companies. Neuland Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Related stocks

PPLPHARMA.NS
PPLPHARMA.NS • India
PIRAMAL PHARMA LIMITED
196.88 INR
2.7B USD 1Y -0.4%
SHILPAMED.BO
SHILPAMED.BO • India
SHILPA MEDICARE LTD.
1,020.35 INR
2.06B USD 1Y +187.4%
GRANULES.NS
GRANULES.NS • India
GRANULES INDIA LIMITED
815.25 INR
2.3B USD 1Y +48.5%
AJANTPHARM.NS
AJANTPHARM.NS • India
AJANTA PHARMA LIMITED
3,410.1 INR
4.4B USD 1Y +40.8%
CAPLIPOINT.BO
CAPLIPOINT.BO • India
CAPLIN POINT LABORATORIES LTD.
2,459.55 INR
1.93B USD 1Y +27.1%
APLLTD.NS
APLLTD.NS • India
ALEMBIC PHARMA LTD
800.95 INR
1.63B USD 1Y -14%
ASTRAZEN.BO
ASTRAZEN.BO • India
ASTRAZENECA PHARMA INDIA LTD.
5,831.85 INR
1.51B USD 1Y -38.5%
EMCURE.NS
EMCURE.NS • India
EMCURE PHARMACEUTICALS L
1,833.5 INR
3.59B USD 1Y +31.4%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
51.7% p.a.
Max Drawdown (5Y)
-46.5%
Sharpe Ratio (5Y)
1.29
Beta Factor
0.28
Size Class
Mega Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 High valuation risk: Avg P/E of 53.8 (Elevated multiple compression risk)
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (51.7% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -84.0% in the extended horizon.
ende